TGA / PMDA / NMPA · Asia-Pacific
vaccine — TGA / PMDA / NMPA regulatory status
vaccine regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 350 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 12-Valent Pneumococcal Conjugate Vaccine | Phase 3 | MAIA Biotechnology | NCT05721456 |
| 17000139BLC3002 | Phase 3 | Janssen-Cilag International N.V | 2023-507187-39-00 |
| 2016L10765-2 | Phase 3 | Chinese Academy of | NCT05091619 |
| 2024/4031 | Phase 3 | George Institute for | 2024-520140-42-00 |
| 212496 | Phase 3 | GSK Glaxo Smith | 2024-512291-34-00 |
| 217848 | Phase 3 | GSK Glaxo Smith | 2023-510196-59-00 |
| 220030 | Phase 3 | GSK Glaxo Smith | 2024-519549-31-00 |
| 222090 | Phase 3 | GSK Glaxo Smith | 2023-509762-38-00 |
| 222253 | Phase 3 | GSK Glaxo Smith | 2023-510190-34-00 |
| 36-71 months old children-experimental EV71 vaccine. | Phase 3 | Sinovac Research and | NCT03909074 |
| 400U /0.5ml EV71 vaccine | Phase 3 | Sinovac Research and | NCT01507857 |
| 9vHPV Vaccine | Phase 3 | Takeda | NCT04313244 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2026104630 | MÉTHODE DE SÉLECTION DOMINANTE PERMANENTE POUR LA GÉNÉRATION DU VIRUS ANKARA DE LA VACCINE MODIFIÉ RECOMBINANT (MVA) | WO |
| 2025238219 | VIRUS MODIFIÉ DE LA VACCINE ANKARA (MVA) CODANT POUR DES NANOPARTICULES PROTÉIQUES PRÉSENTANT DES ANTIGÈNES | WO |
| 12419941 | Poultry drinking water-based vaccine delivery system and method | US |
| 12409220 | Conjugate polypeptides and vaccines for inducing immune responses | US |
| 12404533 | Bioconjugate vaccines' synthesis in prokaryotic cell lysates | US |
| 12357682 | DNA plasmid-launched live-attanuated vaccines for plus-sense singel stranded RNA | US |
| 12357687 | Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same | US |
| 12343388 | Clostridioides difficile TcdB variants, vaccines and methods of use | US |
| 12285478 | Foot-and-mouth disease vaccine | US |
| 12285473 | Cancer vaccines targeting MUC16 and uses thereof | US |
| 12280108 | Vaccines having an antigen and interleukin-21 as an adjuvant | US |
| 12274741 | Cattle fever tick-infestation vaccines and uses thereof | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of vaccine?
vaccine currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get vaccine regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to vaccine?
This spoke lists 350 published programs associated with vaccine in our pipeline index.